This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The past few years have seen important advances in our understanding of the causes of Parkinson’s disease (PD) and in our ability to optimize the symptomatic management of the motor features that characterize this disorder. This supplement reviews progress in several important areas of PD and encompasses some of the basic science that underlies current and future treatment strategies for PD. Although PD remains the focus of attention of much of the movement disorder community, interest has recently been developing in restless leg syndrome (RLS), which may be the most common movement disorder of all. Again, advances have been made both in the understanding and the treatment of this disorder, and these are reviewed in this supplement.
The discovery that MPTP was capable of producing parkinsonism in humans, in other primates, and in rodents provided the opportunity to generate animal models of PD that would be useful both in identifying biochemical mechanisms that may underlie selective dopaminergic degeneration and in the study of pharmacologic agents that may improve symptomatic control of PD. The MPTP primate model of parkinsonism is not a perfect model for the human form of the disease. Nevertheless, it has provided several important insights into the mechanism of action of drugs and, in particular, into their potential toxicity. In this supplement, Jenner reviews the contribution that study of the MPTP model has made to the understanding of the cause and treatment of the motor complications that result from l-dopa use in PD. l-dopa remains the gold standard for the symptomatic management of the dopaminergic-related motor features of PD. Concerns that this drug may have toxicity in vitro have not been supported by any robust data that it is toxic to PD patients. Nevertheless, motor complications, in the form of “wearing-off” and dyskinesias, develop in a …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
